You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 21 - 30 of 205243 results
  1. AAAPT Technology for Improving Chemotherapy

    SBC: SCI-ENGI-MEDCO SOLUTIONS, INC            Topic: NCI

    DESCRIPTION provided by applicant Dysregulation of apoptosis pathways and loss of Human Beta Defensin hBD are the common tactics adapted by cancer cells to circumvent the effects of chemotherapy Consequently high dose of chemotherapy is required to obtain a clinically relevant therapeutic index which in turn compromises safety and develops resistance to therapy The problem is acute p ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. A2A AR Agonists as Adjunct Therapy Against S. aureus Sepsis

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): This is a phase I STTR application to study the efficacy of selective adenosine A2A receptor (A2AR) agonists developed in the laboratories of Adenosine Therapeutics (ATL) in models of Gram-positive bacterial sepsis which will be conducted in the University of Virginia (UVA) laboratories of Dr. Michael Scheld, an expert in the field of infectious disease. Sepsis ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  3. A2A AR Agonists as Adjunct Therapy Against S. aureus Sepsis

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): This is a phase I STTR application to study the efficacy of selective adenosine A2A receptor (A2AR) agonists developed in the laboratories of Adenosine Therapeutics (ATL) in models of Gram-positive bacterial sepsis which will be conducted in the University of Virginia (UVA) laboratories of Dr. Michael Scheld, an expert in the field of infectious disease. Sepsis ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  4. A2a AR Agonists for Rheumatoid Arthritis

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): This is the first revision of a phase I STTR proposal to develop new therapies for the treatment of rheumatoid arthritis (RA). It is collaboration between a biotechnology company, Adenosine Therapeutics, LLC (ATL) based in Charlottesville, VA, and the University of Virginia laboratory of Dr. Donald L. Kimpel, a Rheumatologist experienced in the study of RA. Hum ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  5. A2a AR Agonists for Rheumatoid Arthritis

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): This is the first revision of a phase I STTR proposal to develop new therapies for the treatment of rheumatoid arthritis (RA). It is collaboration between a biotechnology company, Adenosine Therapeutics, LLC (ATL) based in Charlottesville, VA, and the University of Virginia laboratory of Dr. Donald L. Kimpel, a Rheumatologist experienced in the study of RA. Hum ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  6. AAAV Composite Armor Systems

    SBC: Armorworks Enterprises, Inc.            Topic: N/A

    This proposal describes an SBIR Phase II program to develop, optimize, and demonstrate the effectiveness of hybrid composite armor for AAAV. Hybrid composite armor systems, comprised of unique combinations of dissimilar composite materials, offer lightweight protection at a much lower cost than other high performance composites. Ballistic protection data and models for commercial composite armor ...

    SBIR Phase II 2003 Department of DefenseNavy
  7. AAAV Composite Armor Systems

    SBC: Q-PEAK INCORPORATED            Topic: N/A

    Diode-laser arrays operating in the visible region of the spectrum offer advantages for illuminator applications, particularly for night and water penetration capability. Recent developments in diode-laser materials allow operation throughout the visiblespectrum. At this time, red diode-laser technology is more mature than the existing blue-green or violet diode-laser technology. The novel aspe ...

    SBIR Phase I 2001 Department of DefenseNavy
  8. AAAV Mineblast Attenuating Seat

    SBC: Armorworks Enterprises, Inc.            Topic: N/A

    Not Available Sierra-Nevada Research and Development, Inc. proposes to develop a composite material for the production of high performance, compact heat exchange devices. The composite will have a relatively high thermal conductivity coupled with a very high effective heat capacity. This technology will allow for the design of small, high-performance heat exchange devices that are insensitive to ...

    SBIR Phase I 1999 Department of DefenseNavy
  9. AAAV Mineblast Attenuating Seat

    SBC: Armorworks Enterprises, Inc.            Topic: N/A

    N/A

    SBIR Phase II 2000 Department of DefenseNavy
  10. AAAV Multi-Threat Armor System

    SBC: Armorworks Enterprises, Inc.            Topic: N/A

    N/A

    SBIR Phase I 1999 Department of DefenseNavy
US Flag An Official Website of the United States Government